| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression. |
| 掲載誌名 | 正式名：ESMO real world data and digital oncology 略 称：ESMO Real World Data Digit Oncol ISSNコード：29498201/29498201 |
| 巻・号・頁 | 8,pp.100152 |
| 著者・共著者 | K Morimoto, T Yamada, N Furuya, H Tanaka, A Yoshimura, T Oba, M Hibino, T Fukuda, Y Goto, A Nakao, S Ogusu, Y Okazaki, T Harada, T Ota, K Masubuchi, K Mikami, T Hata, S Matsumoto, R Honda, K Date, Y Chihara, K Takayama |
| 発行年月 | 2025/05 |
| 概要 | BACKGROUND:Patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations who experience disease progression after treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) often receive subsequent treatment with either platinum-based chemotherapy (Chemo) or a combination regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). However, whether the efficacy of prior EGFR-TKI treatment influences the outcomes of Chemo or ABCP remains unclear.MATERIALS AND METHODS:Between January 2017 and July 2022, we retrospectively assessed patients with EGFR-mutant NSCLC who received Chemo or ABCP after EGFR-TKIs across 20 institutions.RESULTS:Overall, data of 350 patients with advanced or recurrent EGFR-mutant NSCLC were analyzed. Of these, 262 patients (74.9%) received Chemo, and 88 (25.1%) received ABCP. No significant difference was noted in progression-free survival (PFS) after Chemo between patients who responded to prior EGFR-TKIs for ≥10 months and those who had responded for <10 months (6.1 versus 5.1 months; log-rank test, P = 0.12). In contrast, patients who responded to prior EGFR-TKIs for ≥10 months exhibited a significantly longer PFS to ABCP (8.7 versus 6.7 months; log-rank test, P = 0.002). After propensity score matching, among patients who responded to prior EGFR-TKIs for ≥10 months, the ABCP group had a significantly longer PFS than the Chemo group (8.6 versus 5.3 months; log-rank test, P = 0.008).CONCLUSION:The efficacy of prior EGFR-TKI treatment in patients with EGFR-mutant NSCLC who experience disease progression could be a predictive marker for ABCP rather than Chemo efficacy. |
| DOI | 10.1016/j.esmorw.2025.100152 |
| PMID | 41647697 |